Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 9, 2000

View Archived Issues

Ribozyme repurchases rights to Heptazyme; phase II trial to begin

Cellegy's Rx for sexual dysfunction in women completes phase I/II

Canadian approval sought by Avanir for docosanol cream

Myogen to use SBIR grant for cardiac hypertrophy drug discovery

Two dendritic/cancer cell fusion trials begun by Genzyme Molecular Oncology

Atrix/Elan joint venture for cancer pain therapy selects fentanyl as first development compound

AMG-073 normalizes total serum calcium in hyperparathyroidism

LY-510929: Ligand's new drug candidate for diabetes and obesity

Vardenafil's preclinical profile supports potential in ED; other PDE5 inhibitors in the pipeline

Prophylactic efficacy of FK-463 against P. carinii infection demonstrated in mice

ABT-773 shows promise as antimicrobial agent in bite wound infections

Natural compound improves hypertension

Novel marine antifungal products sought in MycoLogics collaboration

Wyeth-Ayerst presents new SERM with potentially improved therapeutic profile

Analgesic activity of S-19812 assessed in rodent models and reported at OARSI meeting

Potent and selective EP2 receptor agonist with bone anabolic effects presented at ASBMR

Central 5-HT2C receptor agonist exerts proerectile activity in two animal species

Neuroprotective adenosine receptor ligands emerge from Novo Nordisk SAR studies

New triazole antifungal in development for use in deep mycoses

Favorable in vitro profile reported at ICAAC for BCH-13520, a new anti-HIV candidate

Small-molecule inhibitor of MT1-MMP discovered at Parke-Davis

Novel series from Isis Innovation possesses antiprotozoal, antitumor and other activities

Lilly's new 5-ht1F receptor agonists and their use in migraine

Two series synthesized at Boehringer Ingelheim exert sodium channel blockade

Steroid vitronectin receptor ligands discovered during joint research program

AstraZeneca presents new tyrosine kinase inhibitors with immunomodulating activity

Benzenesulfonamide B2 antagonists synthesized at Fournier

NitroMed's newest NO- and/or NO2-containing proton pump inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...